A phase III randomized double-blind placebo-controlled parallel-group multicenter efficacy and safety study of gantenerumab in patients with mild Alzheimer?s disease
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
In this study, we are hoping to learn about the effects, good or bad, of ?gantenerumab? compared with a ?dummy? drug (also called placebo).
Description
In this study, we are hoping to learn about the effects, good or bad, of ?gantenerumab? compared with a ?dummy? drug (also called placebo).
Details
| Condition | Alzheimer's Disease |
|---|---|
| Age | 50years - 90years |
| Clinical Study Identifier | TX3917 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.